185 related articles for article (PubMed ID: 38315795)
21. The impact of resection margin distance on survival and recurrence in pancreatic ductal adenocarcinoma in a retrospective cohort analysis.
Obonyo D; Uslar VN; Münding J; Weyhe D; Tannapfel A
PLoS One; 2023; 18(2):e0281921. PubMed ID: 36800357
[TBL] [Abstract][Full Text] [Related]
22. Impact of Resection Margin Distance on Survival of Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Kim KS; Kwon J; Kim K; Chie EK
Cancer Res Treat; 2017 Jul; 49(3):824-833. PubMed ID: 27561314
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of positive histological margins in patients with pancreatic head ductal adenocarcinoma and lymph node involvement: an international multicentric study.
Joliat GR; Allemann P; Labgaa I; Sulzer J; Vrochides D; Zerbi A; Nappo G; Perinel J; Adham M; Nentwich MF; Izbicki JR; Demartines N; Schäfer M
HPB (Oxford); 2021 Mar; 23(3):379-386. PubMed ID: 32782224
[TBL] [Abstract][Full Text] [Related]
24. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
[TBL] [Abstract][Full Text] [Related]
25. Distal Bile Duct Cancer: Radical (R0 > 1 mm) Resection Achieves Favorable Survival.
Tjaden C; Hinz U; Klaiber U; Heger U; Springfeld C; Goeppert B; Schmidt T; Mehrabi A; Strobel O; Berchtold C; Schneider M; Diener M; Neoptolemos JP; Hackert T; Büchler MW
Ann Surg; 2023 Jan; 277(1):e112-e118. PubMed ID: 34171863
[TBL] [Abstract][Full Text] [Related]
26. Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis.
Rangarajan K; Pucher PH; Armstrong T; Bateman A; Hamady Z
Ann R Coll Surg Engl; 2019 Sep; 101(7):453-462. PubMed ID: 31304767
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic Adenocarcinoma.
Zhang E; Wang L; Shaikh T; Handorf E; Wong JK; Hoffman JP; Reddy S; Cooper HS; Cohen SJ; Dotan E; Meyer JE
Ann Surg Oncol; 2022 Jan; 29(1):354-363. PubMed ID: 34114181
[TBL] [Abstract][Full Text] [Related]
28. Impact of resection margin status on survival in advanced N stage pancreatic cancer - a multi-institutional analysis.
Teske C; Stimpel R; Distler M; Merkel S; Grützmann R; Bolm L; Wellner U; Keck T; Aust DE; Weitz J; Welsch T
Langenbecks Arch Surg; 2021 Aug; 406(5):1481-1489. PubMed ID: 33712875
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study.
Kamarajah SK; White SA; Naffouje SA; Salti GI; Dahdaleh F
Ann Surg Oncol; 2021 Oct; 28(11):6790-6802. PubMed ID: 33786676
[TBL] [Abstract][Full Text] [Related]
30. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review.
Datta J; Willobee BA; Ryon EL; Shah MM; Drebin JA; Kooby DA; Merchant NB
JAMA Surg; 2021 May; 156(5):489-495. PubMed ID: 33533898
[TBL] [Abstract][Full Text] [Related]
31. Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria.
Bolm L; Pisuchpen N; Qadan M; Kambadakone A; Sondermann S; Mueller K; Petruch N; May K; Zelga P; Nebbia M; Michelakos T; Baba T; Roldan J; Harrison JM; Honselmann KC; Keck T; Lillemoe KD; Ferrone CR; Wellner UF; Fernandez-Del Castillo C
Ann Surg; 2022 Aug; 276(2):215-221. PubMed ID: 36036988
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery.
Terlizzi M; Buscail E; Boussari O; Adgié S; Leduc N; Terrebonne E; Smith D; Blanc JF; Lapuyade B; Laurent C; Chiche L; Belleannée G; Le Malicot K; Trouette R; Pouypoudat C; Vendrely V
Acta Oncol; 2021 Sep; 60(9):1114-1121. PubMed ID: 34197269
[TBL] [Abstract][Full Text] [Related]
33. Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group.
Zhang XF; Wu Z; Cloyd J; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha F; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Smith PM; Cho C; Beems M; Schmidt CR; Dillhoff M; Maithel SK; Pawlik TM
Surgery; 2019 Mar; 165(3):548-556. PubMed ID: 30278986
[TBL] [Abstract][Full Text] [Related]
34. Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease.
Cassinotto C; Dohan A; Zogopoulos G; Chiche L; Laurent C; Sa-Cunha A; Cuggia A; Reinhold C; Gallix B
Eur J Radiol; 2017 Oct; 95():33-38. PubMed ID: 28987689
[TBL] [Abstract][Full Text] [Related]
35. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
[TBL] [Abstract][Full Text] [Related]
36. Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study.
van Goor IWJM; Schouten TJ; Verburg DN; Besselink MG; Bonsing BA; Bosscha K; Brosens LAA; Busch OR; Cirkel GA; van Dam RM; Festen S; Koerkamp BG; van der Harst E; de Hingh IHJT; Intven MPW; Kazemier G; Los M; Meijer GJ; de Meijer VE; Nieuwenhuijs VB; Roos D; Schreinemakers JMJ; Stommel MWJ; Verdonk RC; van Santvoort HC; Daamen LA; Molenaar IQ;
Ann Surg; 2024 Jan; 279(1):132-137. PubMed ID: 37450706
[TBL] [Abstract][Full Text] [Related]
37. Improved survival after pancreatic re-resection of positive neck margin in pancreatic cancer patients. A systematic review and network meta-analysis.
Crippa S; Ricci C; Guarneri G; Ingaldi C; Gasparini G; Partelli S; Casadei R; Falconi M
Eur J Surg Oncol; 2021 Jun; 47(6):1258-1266. PubMed ID: 33487492
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma.
de Geus SWL; Kasumova GG; Sachs TE; Ng SC; Kent TS; Moser AJ; Vahrmeijer AL; Callery MP; Tseng JF
HPB (Oxford); 2018 Jun; 20(6):573-581. PubMed ID: 29426635
[TBL] [Abstract][Full Text] [Related]
39. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation.
Sekigami Y; Michelakos T; Fernandez-Del Castillo C; Kontos F; Qadan M; Wo JY; Harrison J; Deshpande V; Catalano O; Lillemoe KD; Hong TS; Ferrone CR
Ann Surg Oncol; 2021 Aug; 28(8):4592-4601. PubMed ID: 33393047
[TBL] [Abstract][Full Text] [Related]
40. Presence of low-grade IPMN at the pancreatic transection margin does not have prognostic significance after resection of IPMN-associated pancreatic adenocarcinoma.
Leonhardt CS; Hinz U; Kaiser J; Hank T; Tjaden C; Bergmann F; Hackert T; Büchler MW; Strobel O
Eur J Surg Oncol; 2023 Jan; 49(1):113-121. PubMed ID: 35965217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
